Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism

Pharmacogenetics and Genomics

Volumn 20, Issue 12, 2010, Pages 759-765

  Siccardi, Marco ^a,c   D'Avolio, Antonio ^a   Nozza, Silvia ^b   Simiele, Marco ^a   Baietto, Lorena ^a   Stefani, Francesca Romana ^a   Moss, Darren ^c   Kwan, Wai San ^c   Castagna, Antonella ^b   Lazzarin, Adriano ^b   Calcagno, Andrea ^a   Bonora, Stefano ^a   Back, David ^c   Di Perri, Giovanni ^a   Owen, Andrew ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

maraviroc; pharmacogenetics; pharmacokinetics; SLCO1B1; uptake transporter

Indexed keywords

EFAVIRENZ; ETRAVIRINE; MARAVIROC; ORGANIC ANION TRANSPORTER 2;

ANIMAL CELL; ARTICLE; DNA POLYMORPHISM; DRUG BLOOD LEVEL; HETEROZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; NONHUMAN; OOCYTE; PRIORITY JOURNAL; XENOPUS LAEVIS;

ADULT; ANIMALS; BIOLOGICAL TRANSPORT; CHROMATOGRAPHY, LIQUID; CYCLOHEXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; OOCYTES; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; SUBSTRATE SPECIFICITY; TRIAZOLES; XENOPUS LAEVIS;

XENOPUS LAEVIS;

EID: 78549265829     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283402efb     Document Type: Article

References (19)

1. Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008; 65 (Suppl 1):27-37.
2. Abel S, Jenkins TM, Whitlock LA, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008; 65 (Suppl 1):38-46. (Pubitemid 351366537)
3. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services 2007, 20, 1-136.
4. McFadyen L, Wade JR, Weatherley B, Chan PLS. Maraviroc (MVC) exposure-effcacy relationship in treatment-experienced HIV-1-infected Patients. 11th European AIDS Conference/EACS Madrid, Spain, 2007.
5. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158:693-705.
6. Kwan WS, Hartkoorn RC, Salcedo-Sora E, Bray P, Khoo S, Back DJ, et al. Determining the substrate specificities of SLCO1A2 and SLCO1B1 for antiretroviral drugs. New Orleans: Workshop on Clinical Pharmacology of HIV Therapy; 2008.
7. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+ C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenetics and Genomics 2005; 15:513-522.
8. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004; 14:429-440.
9. Katz DA, Carr R, Grimm DR, Xiong H, Holley-Shanks R, Mueller T, et al. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Therap 2006; 79:186-196.
10. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenetics and Genomics 2006; 16:873-879.
11. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Therap 2007; 82:726-733.
12. Kohlrausch FB, de Cássia Estrela R, Barroso PF, Suarez-Kurtz G. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. Br J Clin Pharmacol 2009; 69:95-98.
13. Hartkoorn RC, Kwan WS, Shallcross V, Chaikan A, Liptrott N, Egan D, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenetics and Genomics 2010; 20:112-120.
14. Kitamura A, Imai S, Yabuki M, Komuro S. The new acyl-CoA cholesterol acyltransferase inhibitor SMP-797 does not interact with statins via OATP1B1 in human cryopreserved hepatocytes and oocytes expressing systems. Biopharm Drug Dispos 2007; 28:517-525.
15. D'Avolio A, Simiele M, Baietto L, Siccardi M, Sciandra M, Patanella S, et al. A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. Ther Drug Monit 2010; 32:86-92.
16. Center for Drug Evaluation and Research of the US Department of Health and Human Services Food and Drug Administration. Guidance for Industry Bioanalytical Method Validation. 2001.
17. Nakagomi-Hagihara R, Nakai D, Kawai K, Yoshigae Y, Tokui T, Abe T, et al. OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos 2006; 34:862-869.
18. Deng JW, Song IS, Shin HJ, Yeo CW, Cho DY, Shon JH, et al. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenetics and Genomics 2008; 18:424-433.
19. Sari-Chaaf Z, Combes F, Descamps D, Yeni P, Calvez V, Reynes J, et al. Maraviroc boosted (or not) by ritonavir? Pharmacokinetic results from routine therapeutic drug monitoring. Cologne, Germany: EACS; 2009.